嚢胞性線維症治療の北米市場2020-2208

◆英語タイトル:NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028
◆商品コード:INK20MY259
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年3月
◆ページ数:112
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:北米
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe North America cystic fibrosis therapeutics market is estimated to register a CAGR of 10.07% over the projected period of 2020-2028. The market in North America is mainly driven by the presence of significant players in the biotechnology industry such as Vertex Pharmaceuticals Incorporated, Mylan N.V., and many others, who are investing mostly for the development of new technologies that can be used in the advancement of new testing techniques and improvement of the existing ones.

MARKET INSIGHTS
The cystic fibrosis therapeutics market of North America is segmented into the United States and Canada for further surveying growth in the region. In Canada, cystic fibrosis is the most common lethal hereditary disease affecting children and adolescents. It is calculated that out of every 3,600 children, one child has CF in Canada. The estimates show that the number of children, adolescents, and adults, with cystic fibrosis, attending specialized CF clinics, is more than 4,100, and approximately one in 25 Canadians carry an abnormal version of the gene responsible for causing cystic fibrosis. Canada is one of the emerging countries in North America, which holds approximately 11% share in the North American cystic fibrosis therapeutics market.
Further, Canada is one of the largest economies in the world, and its high healthcare expenditure, with universal healthcare sponsored through taxes, is among the best across the globe. Hence, increasing healthcare spending, along with the prevalence of this disease, is estimated to drive market growth. The market constraints in the North American region include monetary obstacles owing to the high cost of technology production.

COMPETITIVE INSIGHTS
AbbVie Inc, Abbott Laboratories, Agilent Technologies, Inc, Johnson & Johnson, Gilead Sciences, Inc, etc. are some of the renowned companies operating in the market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
3.2.2. INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
3.2.3. RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
3.3. KEY RESTRAINTS
3.3.1. STRINGENT REGULATION
3.3.2. LOW AWARENESS AMONG DEVELOPING ECONOMIES
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. PESTEL ANALYSIS
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. KEY INVESTMENT INSIGHTS
5. MARKET BY ROUTE OF ADMINISTRATION
5.1. INHALE
5.2. ORAL
6. MARKET BY DRUG CLASS
6.1. CFTR MODULATORS
6.2. BRONCHODILATORS
6.3. MUCOLYTIC
6.4. PANCREATIC ENZYME SUPPLEMENTS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.2. ABBVIE INC
8.3. AGILENT TECHNOLOGIES INC
8.4. ALLERGAN PLC
8.5. F. HOFFMANN-LA ROCHE
8.6. GILEAD SCIENCES INC
8.7. GLAXOSMITHKLINE PLC
8.8. JOHNSON & JOHNSON
8.9. MYLAN N.V
8.10. NOVARTIS AG
8.11. PERKINELMER
8.12. PFIZER INC
8.13. PHARMAXIS LTD
8.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
8.15. VERTEX PHARMACEUTICALS INCORPORATED



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[嚢胞性線維症治療の北米市場2020-2208]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆